Validated by the GEO dataset, EGFR, MAPK3, RELA, CCND1, ESR1, PTGS2, NR3C1, CYP3A4, and PTPN11 have significant differential expression and were considered to be the core targets of GGD for the treatment of CHD. Here, MAPK3 is linked to coronary artery disorder.